Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
The Journal of Clinical Psychiatry
|
May 20, 2024
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)
Clotilde Guidetti, Sara De Martin, Giulia Serra, et al.
Muscles, Ligaments and Tendons Journal
|
June 6, 2013
Evaluation of a novel topical essential oxygen oil for the treatment of pain in acute tendinopathy and sprains
Marco Pappagallo, John B Leslie, Robert B Raffa, et al.
The Primary Care Companion for CNS Disorders
|
February 23, 2023
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder
Clotilde Guidetti, Giulia Serra, Luca Pani, et al.
Patient Preference and Adherence
|
February 9, 2017
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
Joseph V Pergolizzi, Robert B Raffa, Marco Pappagallo, et al.
Palliative & Supportive Care
|
May 27, 2008
Consensus guideline on parenteral methadone use in pain and palliative care
Lauren Shaiova, Ann Berger, Craig D Blinderman, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 27, 2022
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin
Ezio Bettini, Sara De Martin, Andrea Mattarei, et al.
Drugs in R&D
|
November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Nicola Ferri, Sara De Martin, James Stuart, et al.
Drugs in R&D
|
August 2, 2024
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
Nicola Ferri, Sara De Martin, James Stuart, et al.
Frontiers in Pharmacology
|
May 17, 2021
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study
Sara De Martin, Daniela Gabbia, Franco Folli, et al.
Journal of Clinical Psychopharmacology
|
August 9, 2022
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases
Clotilde Guidetti, Giulia Serra, Luca Pani, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
The Journal of Clinical Psychiatry
|
May 20, 2024
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)
Clotilde Guidetti, Sara De Martin, Giulia Serra, et al.
Muscles, Ligaments and Tendons Journal
|
June 6, 2013
Evaluation of a novel topical essential oxygen oil for the treatment of pain in acute tendinopathy and sprains
Marco Pappagallo, John B Leslie, Robert B Raffa, et al.
The Primary Care Companion for CNS Disorders
|
February 23, 2023
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder
Clotilde Guidetti, Giulia Serra, Luca Pani, et al.
Patient Preference and Adherence
|
February 9, 2017
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
Joseph V Pergolizzi, Robert B Raffa, Marco Pappagallo, et al.
Palliative & Supportive Care
|
May 27, 2008
Consensus guideline on parenteral methadone use in pain and palliative care
Lauren Shaiova, Ann Berger, Craig D Blinderman, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 27, 2022
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin
Ezio Bettini, Sara De Martin, Andrea Mattarei, et al.
Drugs in R&D
|
November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Nicola Ferri, Sara De Martin, James Stuart, et al.
Drugs in R&D
|
August 2, 2024
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
Nicola Ferri, Sara De Martin, James Stuart, et al.
Frontiers in Pharmacology
|
May 17, 2021
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study
Sara De Martin, Daniela Gabbia, Franco Folli, et al.
Journal of Clinical Psychopharmacology
|
August 9, 2022
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases
Clotilde Guidetti, Giulia Serra, Luca Pani, et al.
Page
of 8